Drugs.com - New Drug Approvals

FDA Grants Accelerated Approval for Vanrafia (atrasentan) for Proteinuria Reduction in Primary IgA Nephropathy

Basel, April 3, 2025 – Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of...

May 12, 2025 - 10:14
 0
Basel, April 3, 2025 – Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of...
Read More

Tags:

Previous Article

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a Treatment for Patient...

Next Article

Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for...

Related Posts

FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

FDA Approves Atzumi (dihydroergotamine) Nasal Powder fo...

May 12, 2025  0

Teva and Alvotech Announce FDA Approval of Interchangeability for Selarsdi (ustekinumab-aekn) with Stelara (ustekinumab)

Teva and Alvotech Announce FDA Approval of Interchangea...

May 18, 2025  0

FDA Approves Zevaskyn (prademagene zamikeracel) Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa

FDA Approves Zevaskyn (prademagene zamikeracel) Gene Th...

May 12, 2025  0